$An assessment model for efficacy of autologous CD19 chimeric antigen receptor T-cell therapy and relapse or refractory diffuse large B-cell lymphoma risk$

An assessment model for efficacy of autologous CD19 chimeric antigen receptor T-cell therapy and relapse or refractory diffuse large B-cell lymphoma risk

Saved in:

Bibliographic Details
Main Authors:	Bin Xue, Yifan Liu, Min Zhang, Gangfeng Xiao, Xiu Luo, Lili Zhou, Shiguang Ye, Yan Lu, Wenbin Qian, Li Wang, Ping Li, Aibin Liang, Sihan Zhou, Xiuyuan Hao
Format:	Article
Language:	English
Published:	Wolters Kluwer 2025-01-01
Series:	Chinese Medical Journal
Online Access:	http://journals.lww.com/10.1097/CM9.0000000000003343
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Clinical outcomes of chimeric antigen receptor T-cell therapy following autologous hematopoietic stem cell transplantation in 38 patients with refractory/relapsed primary or secondary central nervous system lymphoma
by: Jiaying Wu, et al.
Published: (2024-11-01)

Real-world use of tafasitamab preceding CD19-directed chimeric antigen receptor T-cell therapy for relapsed or refractory diffuse large B-cell lymphoma
by: Narendranath Epperla, et al.
Published: (2025-01-01)

Multinational retrospective analysis of bridging therapy prior to chimeric antigen receptor t cells for relapsed/refractory acute lymphoblastic leukemia in children and young adults
by: Maike Breidenbach, et al.
Published: (2025-01-01)

Capivasertib enhances chimeric antigen receptor T cell activity in preclinical models of B cell lymphoma
by: Hui-Ju Hsieh, et al.
Published: (2025-03-01)

The Role of Allogeneic Stem Cell Transplantation in Relapsed/Refractory Hodgkin's Lymphoma Patients
by: Evgeny Klyuchnikov, et al.
Published: (2011-01-01)

Several factors that predict the outcome of large B‐cell lymphoma patients who relapse/progress after chimeric antigen receptor (CAR) T‐cell therapy can be identified before cell administration
by: Alice Sýkorová, et al.
Published: (2024-09-01)

Outcome of autologous bone marrow transplant in patients with relapsed and refractory diffuse large B-cell lymphoma in relation with prognostic factor: A single-center experience
by: Fawaz Salim Yousif, et al.
Published: (2024-12-01)

Impact of prior CAR T-cell therapy on mosunetuzumab efficacy in patients with relapsed or refractory B-cell lymphomas
by: Elise A. Chong, et al.
Published: (2025-02-01)

CHIMERIC ANTIGEN RECEPTOR T CELLS FOR THE TREATMENT OF MULTIPLE MYELOMA
by: Ugo Testa, et al.
Published: (2024-10-01)

Outcomes with bridging radiation therapy prior to chimeric antigen receptor T-cell therapy in patients with aggressive large B-cell lymphomas
by: Gohar S. Manzar, et al.
Published: (2025-01-01)

Global outcomes and prognosis for relapsed/refractory mature T-cell and NK-cell lymphomas: results from the PETAL consortium
by: Jessy Xinyi Han, et al.
Published: (2025-02-01)

Successful Bridging to Allogeneic Transplantation With Valemetostat in Two Refractory/relapsed Peripheral T-cell lymphoma patients
by: Gianmarco Bagnato, et al.
Published: (2024-01-01)

A Cost-effectiveness Analysis of Brentuximab Vedotin in Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma
by: Margaret Hux, et al.
Published: (2016-10-01)

Chimeric Antigen Receptor-Modified T Cells for Solid Tumors: Challenges and Prospects
by: Yelei Guo, et al.
Published: (2016-01-01)

Upregulation of CD19 by low‐dose chidamide promotes CAR T cells functionality in B-cell non-Hodgkin lymphoma
by: Ying Ni, et al.
Published: (2025-01-01)

Chimeric antigen receptor with novel intracellular modules improves antitumor performance of T cells
by: Pengju Wang, et al.
Published: (2025-01-01)

Cost drivers associated with autologous stem-cell transplant (ASCT) in patients with relapsed/refractory diffuse large B-cell lymphoma in a Japanese real-world setting: A structural equation model (SEM) analysis 2012-2022.
by: Saaya Tsutsué, et al.
Published: (2025-01-01)

Refractory myasthenia gravis treated with autologous hematopoietic stem cell transplantation
by: Benjamin Beland, et al.
Published: (2025-01-01)

Polatuzumab vedotin combined with bendamustine and rituximab for relapsed/refractory diffuse large B-cell lymphoma: A systematic review protocol.
by: Mohammadreza Eslami, et al.
Published: (2024-01-01)

The Use of Etoposide, Ara-Cytarabine, and Melphalan (EAM) Conditioning Chemotherapy in Autologous Stem Cell Transplantation (ASCT) for a Patient with Relapsed Hodgkin’s Lymphoma
by: Eko A. Pangarsa, et al.
Published: (2021-01-01)

Real-World Characterization of Toxicities and Medication Management in Recipients of CAR T-Cell Therapy for Relapsed or Refractory Large B-Cell Lymphoma in Nova Scotia, Canada
by: Jenna Shaw, et al.
Published: (2024-12-01)

Defining ‘Intention’ in intention-to-treat survival outcomes for chimeric antigen receptor T-cell therapy
by: Charles J. Milrod, et al.
Published: (2025-02-01)

Long-term survival and clinical implications of allogeneic stem cell transplantation in relapse/refractory lymphoma: A 20-year Singapore experience
by: Wei Sheng Joshua Loke, et al.
Published: (2025-01-01)

Granulocyte colony-stimulating factor in neutropenia management after CAR-T cell therapy: A safety and efficacy evaluation in refractory/relapsed B-cell acute lymphoblastic leukemia
by: Xinping Cao, et al.
Published: (2025-01-01)

Screening and characterization of the scFv for chimeric antigen receptor T cells targeting CEA-positive carcinoma
by: Chengcheng Zhang, et al.
Published: (2023-05-01)

From ex vivo to in vivo chimeric antigen T cells manufacturing: new horizons for CAR T-cell based therapy
by: E. Pinto, et al.
Published: (2025-01-01)

The nuclear factor-κ B inhibitor SN50 enhances the efficacy of B-cell maturation antigen-targeted chimeric antigen receptor T-cell therapy
by: Jinlan Long, et al.
Published: (2025-01-01)

Relapsed childhood T-cell acute lymphoblastic leukemia and lymphoblastic lymphoma
by: Andrew D. Hughes, et al.
Published: (2025-01-01)

Genome Editing as a Vehicle to Drive Successful Chimeric Antigen Receptor T Cell Therapies to the Clinic
by: Caitlin R Hopkins, et al.
Published: (2021-12-01)

Herpesvirus Infections After Chimeric Antigen Receptor T-Cell Therapy and Bispecific Antibodies: A Review
by: Joseph Sassine, et al.
Published: (2025-01-01)

Chimeric antigen receptor T cells targeting CD312 as a therapy for acute myeloid leukemia
by: Danni Xie, et al.
Published: (2025-01-01)

First-in-human dose escalation trial to evaluate the clinical safety and efficacy of an anti-MAGEA1 autologous TCR-transgenic T cell therapy in relapsed and refractory solid tumors
by: Ignacio I Wistuba, et al.
Published: (2024-07-01)

Corrigendum: Screening and characterization of the scFv for chimeric antigen receptor T cells targeting CEA-positive carcinoma
by: Chengcheng Zhang, et al.
Published: (2025-01-01)

Safety and efficacy of anti-CD30 CAR-T cell therapy in relapsed/refractory classic Hodgkin lymphoma: a systematic review and meta-analysis
by: Fanqiao Meng, et al.
Published: (2025-01-01)

Autologous haematopoiesis stem cell transplantation (AHSCT) for treatment-refractory autoimmune diseases in children
by: Jasmin Beate Kuemmerle-Deschner, et al.
Published: (2024-07-01)

In vitro functional validation of anti-CD19 chimeric antigen receptor T cells expressing lysine-specific demethylase 1 short hairpin RNA for the treatment of diffuse large B cell lymphoma
by: Zhi Guo, et al.
Published: (2025-01-01)

Advancing Multiple Myeloma Immunotherapy: A Review of Chimeric Antigen Receptor T-Cell and Bispecific T-Cell Engagers Cell Therapies in Revolutionizing Treatment
by: Rahul Navab, et al.
Published: (2025-01-01)

Advancements and Future Directions of Dual-Target Chimeric Antigen Receptor T-Cell Therapy in Preclinical and Clinical Studies
by: Chenyun Zhang, et al.
Published: (2025-01-01)

Siltuximab for chimeric antigen receptor T-cell therapy–related CRS and ICANS: a multicenter retrospective analysis
by: Amneet Bajwa, et al.
Published: (2025-01-01)

Relapsed Mantle Cell Lymphoma Presenting as “Sister Mary Joseph Nodule”
by: Jennifer E. Vaughn, et al.
Published: (2010-01-01)